News

Greg Bailey, the CEO of Juvenescence, discusses Juvenescence and some of the innovations within the longevity space. Interview with 'The Simple BioTech Podcast'. 'The Simple BioTech Podcast' found here....

Juvenescence Limited, a life sciences company focused on modifying aging and increasing human healthspan, is pleased to announce the appointment of Dr. Ellen Donnelly to its Senior Leadership Team. Ellen joins the Juvenescence team as the CEO of the Epigenetics…...

Juvenescence Limited, a life sciences company focused on therapies to modify aging and increasing healthy human longevity, and G3 Therapeutics, a trailblazer biotechnology company leveraging biological big data for drug discovery and development, today announced the formation of Juvenomics Limited,…...

AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, announced today a research collaboration where Sernova will utilize AgeX’s UniverCyteTM gene technology to…...

Dr. Greg Bailey interview with Longevity.Technology: Juvenescence looks to bring on board a completely new mechanism for regeneration;Q3 product launch of a direct-to-consumer ketone ester drink product that is geroprotective, neuroprotective and cardioprotective;Reversing liver failure for people who would otherwise…...

 AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. (Farmington, CT), a biopharmaceutical company pioneering the development of mesenchymal stem cells (hES-MSC) derived from…...

Program will utilize AgeX’s proprietary PureStem® cell derivation and manufacturing technology platform.Goal of developing cellular therapies for Huntington’s disease and potentially Parkinson’s, Alzheimer’s and other neurological conditions.Builds on University’s research in neural stem cell transplantation for Huntington’s disease, including safety and…...

First research collaboration for immunotolerance UniverCyteTM technology platform, marking launch of new business development and collaboration strategySecures milestone collaboration in Japan, where cell therapy R&D is advancing rapidly in a favourable regulatory and commercial environmentUniverCyte platform has the potential to deliver…...

Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico's machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated…...

NetraMark Corp., a next generation AI + health data technology company and Juvenescence Limited, a life sciences company utilizing expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human…...

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, issued a letter to shareholders from Michael D. West, PhD, founder and CEO, and Gregory Bailey, MD, Chairman, reflecting on progress…...

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, and Juvenescence, a life sciences company developing therapeutics and technologies to treat diseases of aging and to increase human longevity, announce the publication…...